UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
Key Details
- 1AI stratified patients by tumor cell density on diagnostic biopsy slides in a post-hoc ARISTOTLE phase III trial analysis (n=414).
- 2Adding irinotecan reduced recurrence by 43% and death by 50% over 5 years in high-tumor-cell-density cases; no benefit in low-density cases.
- 3AI tool ('Octopath') enables rapid, large-scale analysis of digital pathology slides.
- 4Manual quantification was previously impractical for large studies; automation enables scalable, individualized treatment decisions.
- 5Further verification and studies are needed before clinical deployment.
Why It Matters
AI-driven analysis of biopsy pathology can enable more precise, personalized cancer therapy selection, sparing patients from unnecessary side effects and improving survival. This study underscores AI's value in digital pathology for oncology decision-making.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
Duke Receives $25M to Lead National Trustworthy AI Hub for Dementia and Aging
Duke University has launched a $25 million national center to make AI for aging and dementia clinically robust and trustworthy.